Company: BSX
Filing Date: 2025-08-01
Form Type: 10-Q
Source: 0000885725-25-000041
Chunk: 38

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-08-01
Form: 10-Q
Item: Part I, Item 1
Chunk 38
---
ILITIES AND STOCKHOLDERS’ EQUITY  Current liabilities:  Current debt obligations$480 $1,778 Accounts payable962 960 Accrued expenses2,797 2,773 Other current liabilities952 887 Total current liabilities5,190 6,399 Long-term debt11,107 8,968 Deferred tax liabilities226 155 Other long-term liabilities2,383 1,870 Commitments and contingenciesStockholders’ equity  Preferred stock, $0.01 par value - authorized 50,000,000 shares - 0 shares issued as of June 30, 2025 and December 31, 2024— — Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,743,632,871 shares as of June 30, 2025 and 1,737,846,196 shares as of December 31, 202417 17 Treasury stock, at cost - 263,289,848 shares as of June 30, 2025 and December 31, 2024(2,251)(2,251)Additional paid-in capital21,230 21,056 Retained earnings4,144 2,673 Accumulated other comprehensive income (loss), net of tax(722)275 Total stockholders’ equity22,418 21,770 Noncontrolling interests235 233 Total equity22,653 22,003 TOTAL LIABILITIES AND EQUITY$41,559 $39,395 

Refer to notes to the unaudited consolidated financial statements. Amounts may not add due to rounding.

5

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)

Three Months EndedJune 30,Six Months EndedJune 30,(in millions, except share data)2025202420252024Common stock shares issuedBeginning1,742,488,328 1,733,293,885 1,737,846,196 1,729,000,224 Impact of stock-based compensation plans1,144,543 1,035,859 5,786,675 5,329,520 Ending1,743,632,871 1,734,329,744 1,743,